AB's AD candidate meets Phase II endpoint

AB Science S.A. (Euronext:AB) said masitinib met the primary endpoint of significantly improving ADAS-Cog scores from baseline to week 24 vs. placebo in a Phase II trial to treat Alzheimer's disease (...